Hainan Poly Pharm. Co., Ltd

SZSE:300630 Stock Report

Market Cap: CN¥3.1b

Hainan Poly Pharm Balance Sheet Health

Financial Health criteria checks 2/6

Hainan Poly Pharm has a total shareholder equity of CN¥2.8B and total debt of CN¥2.7B, which brings its debt-to-equity ratio to 96.7%. Its total assets and total liabilities are CN¥6.3B and CN¥3.4B respectively.

Key information

96.7%

Debt to equity ratio

CN¥2.72b

Debt

Interest coverage ration/a
CashCN¥331.37m
EquityCN¥2.81b
Total liabilitiesCN¥3.45b
Total assetsCN¥6.25b

Recent financial health updates

Recent updates

Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 26% Dip In Price Shows Sentiment Is Matching Revenues

Dec 18
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 26% Dip In Price Shows Sentiment Is Matching Revenues

Hainan Poly Pharm (SZSE:300630) Is Making Moderate Use Of Debt

Dec 02
Hainan Poly Pharm (SZSE:300630) Is Making Moderate Use Of Debt

What Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 46% Share Price Gain Is Not Telling You

Oct 08
What Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 46% Share Price Gain Is Not Telling You

Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Aug 16
Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

Apr 21
It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Mar 06
A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Financial Position Analysis

Short Term Liabilities: 300630's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.4B).

Long Term Liabilities: 300630's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥2.1B).


Debt to Equity History and Analysis

Debt Level: 300630's net debt to equity ratio (84.9%) is considered high.

Reducing Debt: 300630's debt to equity ratio has increased from 12.7% to 96.7% over the past 5 years.

Debt Coverage: 300630's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 300630's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 19:17
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hainan Poly Pharm. Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Zhizhong JingChina Merchants Securities Co. Ltd.
Jiaxi XuIndustrial Securities Co. Ltd.